Physicochemical properties of phosphorothioate oligodeoxynucleotides.
Reads0
Chats0
TLDR
The syntheses, melting temperatures, and nuclease susceptibilities of a series of phosphorothioate ODN analogs are reported, providing a rational basis for the S-dC/G sequences as potential effective anti-AIDS agents.Abstract:
We have recently shown that phosphorothioate (PS) oligodeoxynucleotide (ODN) analogs, unlike their normal congeners, exhibit significant anti-HIV activity (Matsukura et al., (1987) Proc. Natl. Acad. Sci. USA 84, 7706-7710). We now report the syntheses, melting temperatures (Tm), and nuclease susceptibilities of a series of phosphorothioate ODN analogs. These include all-PS duplexes, duplexes with one normal chain and the other chain either all-PS, or end-capped with several PS groups at both 3' and 5' ends. The DNase susceptibilities of the S-ODNs are much less than the normal phosphodiesters, but by contrast duplexes of poly-rA with S-dT40 are much more susceptible to RNase H digestion. The Tm's for AT base pairs of S-ODNs are significantly depressed relative to normals, while GC base pairs show much less Tm depression. The Tm's of S-dT oligomers with poly-rA are reduced relative to the duplexes with normal dA oligomers. These results have significance for the biological properties of these analogs as anti-message inhibitors of gene expression, and provide a rational basis for the S-dC/G sequences as potential effective anti-AIDS agents.read more
Citations
More filters
Journal ArticleDOI
CpG Motifs in Bacterial DNA and Their Immune Effects
TL;DR: Oligodeoxynucleotides containing CpG ODN enhance the development of acquired immune responses for prophylactic and therapeutic vaccination and protect against lethal challenge with a wide variety of pathogens.
Journal ArticleDOI
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Cy A. Stein,Yung-Chi Cheng +1 more
TL;DR: The potential use of phosphorothioate oligos as inhibitors of viral replication is highlighted and these are examples of oligos that are being considered for clinical therapeutic trials and meet some, but not all, of these criteria.
Journal ArticleDOI
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett,Eric E. Swayze +1 more
TL;DR: The molecular mechanisms by which antisense oligonucleotides can be designed to modulate RNA function in mammalian cells and how synthetic oligon nucleotides behave in the body are focused on.
Journal ArticleDOI
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
TL;DR: CpG ODN provide a signal to switch on Th1-dominated responses to coadministered antigen and are potential adjuvants for human vaccines to elicit protective Th1 immunity.
Patent
Immunostimulatory nucleic acid molecules
TL;DR: In this paper, nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.
Related Papers (5)
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Cy A. Stein,Yung-Chi Cheng +1 more